SCHEMBL12203972

SCHEMBL12203972

Cc1cc(Br)c(CN2CCCC2)c(Br)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.49
▸ HRH3 Q9Y5N1 3/20 0.47
▸ KMT2A Q03164 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CFB P00751 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11620021 0.77 RAB9A (0.43) RAB9AHRH3KMT2AALDH1A1NPC1
SCHEMBL12203968 0.76 KMT2A (0.48) RAB9AKMT2AALDH1A1NPC1HPGD
SCHEMBL11620842 0.75 KDM4E (0.43) RAB9AKMT2AALDH1A1NPC1HPGD
SCHEMBL11634143 0.75 KDM4E (0.43) RAB9AKMT2AALDH1A1NPC1HPGD
SCHEMBL15872041 0.72 HRH3 (0.54) HRH3KMT2AALDH1A1TDP1SMN1; SMN2
SCHEMBL23783633 0.72 GAA (0.54) HRH3KMT2AALDH1A1TDP1MEN1
SCHEMBL3352630 0.71 HRH3 (0.58) HRH3ALDH1A1TDP1SMN1; SMN2KDM4E
SCHEMBL13038515 0.69 KMT2A (0.50) HRH3KMT2AALDH1A1HSD17B10TDP1
SCHEMBL11620159 0.69 RAB9A (0.59) RAB9AKMT2AALDH1A1NPC1HPGD
SCHEMBL1427476 0.68 GFER (0.54) KMT2AALDH1A1HSD17B10TDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034949-B2 Pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-11 — — US disclosed
US-8034949-B2 Pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-11 — — US disclosed
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-07-19 — — US disclosed
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same CNR1, CNR2, OPRD1 RAB9A 766/4885HRH3 5/4885KMT2A 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback